FILE PHOTO: The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski/File Photo
September 29, 2021
(Reuters) – AstraZeneca said on Wednesday its newly acquired Alexion division will purchase the remaining equity in drugmaker Caelum Biosciences in a deal that could be worth up to $500 million, expanding its access into rare-disease treatments.
The Anglo-Swedish drugmaker said it would take forward Caelum’s late-stage trial of a potential medicine to treat AL amyloidosis, a rare disease that affects the heart, kidneys and other organs.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)
Source: One America News Network
